Sommaire

Numéro précédent | Numéro suivant

• • ·A proportionate response to H7N9

    Page :465

     
• • ·AS03-adjuvanted influenza vaccine in elderly people

    Page :466-467

    Julie E Ledgerwood

     
• • ·Acute hepatitis C: to treat or not to treat

    Page :467-468

    Niharika R Samala, Marc G Ghany

     
• • ·Landscape of neglected tropical diseases: getting it right

    Page :469-470

    Lisette van Lieshout, Maria Yazdanbakhsh

    
• • ·The end of the road for empirical antifungal treatment?

    Page :470-472

    J Peter Donnelly, Johan Maertens

    
• • ·HIV epidemic in men who have sex with men in Philippines

    Page :472-473

    Allen GP Ross, Rossana A Ditangco, Jose Gerard Belimac, Remigio M Olveda, Edelwisa Segubre Mercado, Gary D Rogers, Allan W Cripps, Alfred Lam, Suzanne M Crowe

    
• • ·Corrections

    Page :473

    
• • ·Congenital neurosyphilis

    Page :474

    David JM Wright

    
• • ·Congenital neurosyphilis

    Page :474-475

    Regina Célia de Souza Campos Fernandes, Enrique Medina-Acosta

    
• • ·Congenital neurosyphilis – Authors’ reply

    Page :475-476

    Sónia Silva, Raquel Henriques, Maria José Borrego, João Paulo Gomes, Eulália Afonso

    
• • ·Pretreatment HIV-1 drug resistance in Africa

    Page :476

    Raph L Hamers, Cissy Kityo, Kim CE Sigaloff, Tobias F Rinke de Wit

    
• • ·The world waits for H7N9 to yield up its secrets

    Page :477-478

    David Holmes

     
• • ·Challenges and targets for measles elimination

    Page :479-480

    Talha Burki

     
• • ·Highlights from the 23rd ECCMID

    Page :481-482

    Peter Hayward

    Plan Plan  
• • ·Infectious disease surveillance update

    Page :482

    Nawsheen Boodhun

    Plan Plan
• • ·Research brief

    Page :483

    Jane Bradbury

    Plan Plan  
• • ·The unfinished history of tuberculosis

    Page :484

    Talha Burki

     
• • ·AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

    Page :485-496

    Janet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, Meral Esen, Odile Launay, Geert Leroux-Roels, Guillermo M Ruiz-Palacios, Gerrit A van Essen, Adrian Caplanusi, Carine Claeys, Christelle Durand, Xavier Duval, Mohamed El Idrissi, Ann R Falsey, Gregory Feldman, Sharon E Frey, Florence Galtier, Shinn-Jang Hwang, Bruce L Innis, Martina Kovac, Peter Kremsner, Shelly McNeil, Andrzej Nowakowski, Jan Hendrik Richardus, Andrew Trofa, Lidia Oostvogels, for the Influence65 study group

    Résumé Résumé Plan Plan   
• • ·Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial

    Page :497-506

    Katja Deterding, Norbert Grüner, Peter Buggisch, Johannes Wiegand, Peter R Galle, Ulrich Spengler, Holger Hinrichsen, Thomas Berg, Andrej Potthoff, Nisar Malek, Anika Großhennig, Armin Koch, Helmut Diepolder, Stefan Lüth, Sandra Feyerabend, Maria Christina Jung, Magdalena Rogalska-Taranta, Verena Schlaphoff, Markus Cornberg, Michael P Manns, Heiner Wedemeyer, for The Hep-Net Acute HCV-III Study Group

    Résumé Résumé Plan Plan   
• • ·Soil-transmitted helminth infection in South America: a systematic review and geostatistical meta-analysis

    Page :507-518

    Frédérique Chammartin, Ronaldo GC Scholte, Luiz H Guimarães, Marcel Tanner, Jürg Utzinger, Penelope Vounatsou

    Résumé Résumé Plan Plan   
• • ·Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial

    Page :519-528

    C Orla Morrissey, Sharon C-A Chen, Tania C Sorrell, Samuel Milliken, Peter G Bardy, Kenneth F Bradstock, Jeffrey Szer, Catriona L Halliday, Nicole M Gilroy, John Moore, Anthony P Schwarer, Stephen Guy, Ashish Bajel, Adrian R Tramontana, Timothy Spelman, Monica A Slavin, for the Australasian Leukaemia Lymphoma Group and the Australia and New Zealand Mycology Interest Group

    Résumé Résumé Plan Plan   
• • ·Drug-resistant tuberculosis: time for visionary political leadership

    Page :529-539

    Ibrahim Abubakar, Matteo Zignol, Dennis Falzon, Mario Raviglione, Lucica Ditiu, Susan Masham, Ifedayo Adetifa, Nathan Ford, Helen Cox, Stephen D Lawn, Ben J Marais, Timothy D McHugh, Peter Mwaba, Matthew Bates, Marc Lipman, Lynn Zijenah, Simon Logan, Ruth McNerney, Adam Zumla, Krishna Sarda, Payam Nahid, Michael Hoelscher, Michel Pletschette, Ziad A Memish, Peter Kim, Richard Hafner, Stewart Cole, Giovanni Battista Migliori, Markus Maeurer, Marco Schito, Alimuddin Zumla

    Résumé Résumé Plan Plan  
• • ·Engaging communities in tuberculosis research

    Page :540-545

    Renaud F Boulanger, Stephanie Seidel, Erica Lessem, Lee Pyne-Mercier, Sharon D Williams, Laia Ruiz Mingote, Cherise Scott, Alicia Y Chou, James V Lavery, on behalf of the Critical Path to TB Drug Regimens’ Stakeholder and Community Engagement Workgroup †

    Résumé Résumé Plan Plan
• • ·Rapid diagnostic tests for neurological infections in central Africa

    Page :546-558

    Cedric P Yansouni, Emmanuel Bottieau, Pascal Lutumba, Andrea S Winkler, Lut Lynen, Philippe Büscher, Jan Jacobs, Philippe Gillet, Veerle Lejon, Emilie Alirol, Katja Polman, Jürg Utzinger, Michael A Miles, Rosanna W Peeling, Jean-Jacques Muyembe, François Chappuis, Marleen Boelaert

    Résumé Résumé Plan Plan